Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04569045
Other study ID # RDCT-CNFL
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date August 20, 2020
Est. completion date December 10, 2021

Study information

Verified date February 2021
Source SciVision Biotech Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this study is to evaluate the safety and effectiveness of pain relief of modified sodium hyaluronate gel for injection when used for the correction of moderate or severe nasolabial folds.


Description:

One hundred and thirty patients were enrolled and there two sides of nasolabial folds (NLF) were randomized to receive HA with lidocaine or HA. The primary outcome was immediate visual analogue scale (VAS) of pain evaluated after injection for both NLF sides. Secondary outcomes including VAS pain, wrinkle severity rating scale (WSRS), global aesthetic improvement scale (GAIS) and AE were observed at 1, 3, 6, 9, 12 follow-ups.


Recruitment information / eligibility

Status Completed
Enrollment 130
Est. completion date December 10, 2021
Est. primary completion date December 4, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Age 18 to 65 years of male or female - Wrinkle Severity Rating Scale (WSRS) of bilateral nasolabial folds graded 3 or 4 by blinded evaluator (moderate to severe bilateral nasolabial fold), consistent grade of bilateral nasolabial folds, and the grades approved by the physician who perform the treatment - Agree not to undergo any other under-eye facial surgery (including nose) during the study period Exclusion Criteria: - Injection site with infection or other skin diseases present which may affect the evaluation - With medical history of chromatosis, discoloration, keloid formation, hypertrophic scarring at nasolabial folds - With permanent implants or planning to receive permanent implants during the study period at the injection sites - Hyaluronate facial dermal implant injection or other impermanent dermal fillers injection at injection sites within the past 12 months - With under-eye facial Botox or fat injection within the past 6 months or planning to receive under-eye facial Botox or fat injection during the study period - With under-eye facial chemical or lasers peeling, non-invasive skin tightening, thermocool within the past 3 months or planning to receive these aesthetic procedures during the study period - With prescription medication for nasolabial fold treatment, topical corticosteroid, skinirritating topical products or pigmentation products within the past 2 weeks or planning to take these medication or products during the study period - With systemic immunosuppressive therapy or systemic corticosteroids within the past 2 months or planning to receive these therapies during the study period (subjects who have received inhaled/intranasal corticosteroids could be considered to include.) - Severe liver or kidney defects (such as the value of ALT or AST over 1.5 folds of upper limit of normal value; the value of creatinine over 1.5 folds of upper limit of normal value) - With clinical meaningful coagulation disorders, underdoing anticoagulant treatment or within the past 10 days, or taking blood circulation promotion and blood stasis removement medications - With epilepsy or porphyria - With congenital or idiopathic methemoglobinemia or glucose-6-phosphate dehydrogenase deficiency - With the need to take b-blocker during the study period - With severe atrioventricular block (type 2 second-degree AV block and third-degree AV block) - With analgesic dependence, analgesics within the past 2 weeks or planning to receive analgesics during the study period - With orthodontics, tooth extraction, tooth implantation (extraction or implantation of tooth anterior to the second premolar) or planning to receive these procedures during the study - With history of hypersensitivity or allergy to lidocaine, amide anesthetics, hyaluronic acid or any component of the device; Gram-positive bacterial or Streptococcus proteins; other severe hypersensitivity history unsuitable for participating in the study - Planning to undergo any surgery which may cause significant body weight change (such as bariatric surgery) or take any medication which may cause significant body weight change - Pregnant, planning pregnancy or in breastfeeding females - With syphilis or HIV infection - Participated in clinical study of other device or drug and have not terminated within the past 30 days -Other circumstances which judged to be unsuitable for participating in the study by the investigator

Study Design


Related Conditions & MeSH terms


Intervention

Device:
HA+Lidocaine
20 mg
HA
20 mg

Locations

Country Name City State
China Beijing Beijing
China Shanghai Shanghai

Sponsors (1)

Lead Sponsor Collaborator
SciVision Biotech Inc.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Immediate VAS pain evaluated after injection for both NLF sides The VAS scale uses a 100 mm line labelled at '0' with 'no pain' and '100' with 'worst pain'. Immediate post-injection
Secondary VAS pain evaluated 15, 30, 45 and 60 minutes after injection for both NLF sides The VAS scale uses a 100 mm line labelled at '0' with 'no pain' and '100' with 'worst pain'. 15, 30, 45 and 60 minutes post-injection
Secondary On-site WSRS evaluated by site blinded-evaluator at 1, 3, 6, 9 and 12 months Evaluators assess the wrinkle severity of nasolabial folds on site or photographically with 5 graded scale,1 to 5 was represented 'absent' to 'extreme'. 1, 3, 6, 9 and 12 months post-injection
Secondary GAIS evaluated photographically by independent blinded-evaluator at 1, 3, 6, 9 and 12 months Evaluators and subjects assess the improvement of correction with 5 graded scale,1 to 5 was represented 'exceptional improvement' to 'worsened'. 1, 3, 6, 9 and 12 months post-injection
Secondary Adverse events reported from the baseline and during the study period The safety assessment was based on reports of adverse events, defined as any unwanted events whether it was thought to be related to the study drugs or not, were recorded during each follow up and at any time the patient reported an event to the investigator during the study period. 1, 3, 6, 9 and 12 months post-injection
See also
  Status Clinical Trial Phase
Completed NCT06355817 - Distraction Techniques in Periocular Anesthesia: Tapping vs Vibration N/A
Completed NCT01688648 - Comparison Between Lidocaine, Dexmedetomidine, and Their Combined Infusion in Subjects Undergoing Coronary Artery Bypass Graft N/A
Completed NCT04692896 - Effect of Different Concentrations of Lidocaine in Relieving Pain in Wide Awake Hand Surgery Using Tumescence Phase 1
Recruiting NCT06088875 - Nebulization Versus Spray-as-You-Go Airway Topical Anesthesia Using Dexmedetomidine and Lidocaine Mixture During Awake Flexible Fiberoptic Intubation in Temporomandibular Ankylosis N/A
Recruiting NCT04169854 - Pre-emptive Topical Lidocaine 5% Plaster for Prevention of Post-craniotomy Pain Phase 3
Completed NCT04076865 - Evaluation of the Effect Induced by Repeated Administration of Topical Local Anaesthetic (EMLA) on Itch N/A
Completed NCT02987985 - Efficacy of Opioid-free Anesthesia in Reducing Postoperative Respiratory Depression in Children Undergoing Tonsillectomy Phase 3
Recruiting NCT05089526 - Opioid-free Anesthesia in Laparoscopic Cholecystectomies N/A
Recruiting NCT03871478 - Comparing the Efficacy of Local Anesthetics in Mohs Surgery N/A
Recruiting NCT03666299 - Lidocaine Infusion for Postthoracotomy Pain Syndrome N/A
Recruiting NCT03673163 - Lidocaine Infusion for Pain After Herniotomy N/A
Recruiting NCT05158348 - A Comparative Study to Measure the Effect of Nebulized Dexmedetomidine Phase 3
Completed NCT06135688 - Effects of Lidocaine Bolus and Infusion on Bispectral Index Values and Spectrum During Anesthesia Maintenance
Completed NCT04008433 - Median Effective Dose of Lidocaine for the Prevention of Pain Caused by the Injection of Propofol Formulated With Medium-/Long-chain Triglycerides N/A
Recruiting NCT04622904 - Lidocaine and Magnesium and Ketamine in Gynecological Surgery N/A
Recruiting NCT05717361 - Opioid Sparing Anesthesia in Cervical Spine Surgery N/A
Withdrawn NCT04359017 - Systemic Absorption of Lidocaine After Hematoma Block Phase 4
Recruiting NCT04144933 - Effect of Multimodal Opioid-free Anesthesia on Return of Bowel Function in Laparoscopic Colorectal Surgery Phase 3
Recruiting NCT05243940 - Opioid-free Anesthesia in Thyroidectomies N/A
Completed NCT05484687 - Effect of Intravenous Infusion of Lidocaine on Patients Undergoing Radical Resection of Colorectal Tumors N/A